Inicio>>Signaling Pathways>> PROTAC>>Thalidomide 4'-oxyacetamide-PEG3-amine

Thalidomide 4'-oxyacetamide-PEG3-amine

Catalog No.GC50462

La talidomida 4'-oxiacetamida-PEG3-amina es un conjugado ligando-enlazador de ligasa E3 sintetizado que incorpora el ligando cereblon basado en talidomida y el enlazador PEG de 3 unidades utilizado en la tecnologÍa PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide 4'-oxyacetamide-PEG3-amine Chemical Structure

Cas No.: 2245697-84-9

Tamaño Precio Disponibilidad Cantidad
25mg
84,00 $
Disponible
100mg
245,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Functionalized cereblon ligand for PROTACsup>® research and development; incorporates an E3 ligase ligand plus a PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 1 PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Winter et al (2015) Functionalized Cereblon ligand for PROTACs; incorporates an E3 ligase ligand and a linker used in PROTAC technology. Science 348 1376 PMID:25999370 |Salami et al (2017) Waste disposal-An attractive strategy for cancer therapy. Science 355 1163 PMID:28302825

Reseñas

Review for Thalidomide 4'-oxyacetamide-PEG3-amine

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide 4'-oxyacetamide-PEG3-amine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.